Investors in Healthtec

"Additio Investment Group is a global Syndicate of Healthcare & Life Sciences Investors that support high-integrity entrepreneurs with the potential to build great businesses. We pay particular attention to EU based opportunities that are in line with our health/care industry expertise and where we can add direct value, mainly: MedTech, and Digital Health/HealthTech with a particular clinical relevance. Average ticket size of €300-500K. AiG1 (fund 1) has been successfully allocated with a high profile portfolio of 5 companies. Our Partners are committed to hands-on value creation to our Portfolio through capital allocation, expertise and access to a valuable international Network."

Ship2B Ventures is a venture capital firm that invests in impact startups. As impact investors, they are dedicated to achieving triple profitability—economic, social, and environmental. Integrating principles from both venture capital and impact investing realms, they aim to maximize financial returns while deliberately creating, managing, and measuring the positive impact of their investments.

Invivo Partners, founded by Albert Ferrer and Luis Pareras, is a management company specializing in early-stage investments in the healthcare sector. They leverage a team of highly skilled professionals with expertise in scientific, technical, and financial analysis, supported by a strong network within the health ecosystem. Managed under Invivo Partners, Invivo Ventures operates based on the success of their initial fund, Healthequity, which closed at 60 million euros after registration with CNMV in 2019. Backed by prominent institutions and private investors, Invivo Partners has achieved notable exits and significant funding for their portfolio companies, emphasizing groundbreaking scientific innovations. Their strategic insights into Technology Transfer and ability to identify emerging trends position them as a leading player in Europe's Technology Transfer landscape.

The investment firm focuses on early-stage and growth-oriented companies located primarily within the region. They seek businesses with scalable ideas and clear competitive advantages, led by driven entrepreneurs willing to take significant risks. Emphasizing sustainability, they assess teams based on their diverse skills and experience. Investments are made through equity, convertible debentures, or Crown loans, with a preference for initiatives linked to growth in Halland and collaborations with Halmstad University. Initial investments typically start at SEK 500,000, with a maximum amount per company limited to one additional investment. Crown loans are offered up to SEK 500,000 annually per company, capped at SEK 250,000. Their investment strategy includes planning for potential exits within a six-year timeframe.

They partner with entrepreneurs and scientists who challenge conventional thinking and tackle complex problems. Their focus is on investing in innovative solutions with the potential to disrupt market structures. They prioritize businesses that embody agility, scalability, and sustainability in their operations and growth strategies.

Creandum, founded after the dotcom bubble and having thrived through the 2008/9 economic crisis, continues to invest steadily despite recent market conditions, believing top founders can emerge anytime. They've witnessed significant growth in the European tech market over 20 years. Now, they proudly announce the closing of Creandum VII, a €500m fund to support Europe's top Seed and Series A startups. Their disciplined, generalist approach focuses on partnering with the best entrepreneurs to build future global, category-defining companies.

Sweet Capital is a private early-stage investment fund established by the founders of King.com (known for Candy Crush) following their $5.9 billion acquisition by Activision Blizzard in 2015. They exclusively invest their own capital and leverage their extensive entrepreneurial backgrounds to support every founder they back with valuable, firsthand experiences.

Founded in 1997, Earlybird invests in all development and growth phases of technology companies. Among the most experienced venture investors in Europe, Earlybird offers its portfolio companies not only financial resources but also strategic support plus access to an international network and capital markets. Earlybird Venture Capital has grown to four autonomous, dedicated and specialized teams, focusing on different geographies and sectors.

Founded in 2012, first as an angel fund, by Filip Dames and Christian Meermann, Cherry is an early-stage venture capital firm based in Berlin, London and Stockholm. They’re an investment team of former entrepreneurs and operators who’ve built fast-scaling companies such as Zalando, Spotify and Uber. At the moment, their entire team is working with +100 active portfolio companies across Europe with the support of their extensive entrepreneur pool of Europe’s top founders and operators from Dropbox, Zalando, Spotify, N26, Skype, Supercell, Wolt, Doordash and others.

BAF is a venture capital firm which invests in startups, early stage companies and SMEs in Baltic region. Business Angel Fund's investment size varies between 50k and 600k EUR. BAF invests along with Business Angels same conditions .

Segulah Medical Acceleration specializes in investing in and nurturing transformative businesses focused on medical technologies and associated value chain solutions. These companies leverage cutting-edge research to develop real-world applications in areas like medical devices, diagnostics, and life science tools. Segulah Medical Acceleration plays a pivotal role in bridging the gap between innovative concepts and commercial validation, facilitating the global market entry of advanced medical research solutions.

Karolinska Development AB is an investment firm focused on identifying and nurturing medical innovations. It invests in companies that develop these innovations into products aimed at improving patient outcomes and achieving robust financial returns. The company leverages access to cutting-edge medical research from institutions like the Karolinska Institutet, aiming to build successful ventures around leading scientists. Karolinska Development manages a portfolio of 10 companies focused on innovative treatments for severe diseases. Its leadership includes venture capital experts, experienced entrepreneurs, and a global network of specialists.